This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brent, T. P. Search for Related Content PubMed PubMed Citation Articles by Brent, T. P.

Inactivation of Purified Human O⁶-Alkylguanine-DNA Alkyltransferase by Alkylating Agents or Alkylated DNA¹

Department of Biochemical and Clinical Pharmacology, St. Jude Children's Research Hospital, Memphis, Tennessee 38101

O⁶-Alkylguanine-DNA alkyltransferase partially purified from cultured human lymphoblasts (CEM-CCRF line) was inactivated with DNA substrates that had been treated separately with five methylating agents or with five chloroethylnitrosoureas. The extent of depletion of the transferase by alkylated DNA was compared with its inactivation by direct reaction with these ten agents. As expected, DNA substrates treated with methylating agents that efficiently produce O⁶-methylguanine were most effective in depleting the transferase, as was DNA pretreated with 1-(2-chloroethyl)-1-nitrosourea, 1,3-bis(2-chloroethyl)-1-nitrosourea, and chlorozotocin, agents presumed to form O⁶-chloroethylguanine as well as O⁶-hydroxyethylguanine in DNA. Unexpectedly, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea and 1-trans-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea were relatively ineffective in producing a DNA substrate that would inactivate the transferase, suggesting that both agents produce low steady-state levels of O⁶-alkylguanine. All of the agents tested were capable of inactivating the transferase by direct alkylation, although the efficiency of this activity ranges widely. We conclude that simple methylating agents and the cross-linking chloroethylnitrosoureas can inactivate O⁶-alkylguanine-DNA alkyltransferase both directly and indirectly, affording two mechanisms by which such agents could modulate their own cytotoxicity.

¹ This research was supported by Grants CA 14799, CA 21765, and CA 36888 from the National Cancer Institute and by the American Lebanese Syrian Associated Charities.

² To whom requests for reprints should be addressed.

Received 10/25/85. Revised 1/28/86. Accepted 1/29/86.

This article has been cited by other articles:

				A. A. Brandes, S. Turazzi, U. Basso, L. M. Pasetto, B. Guglielmi, L. Volpin, P. Iuzzolino, P. Amista, G. Pinna, R. Scienza, et al. A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme Neurology, June 25, 2002; 58(12): 1759 - 1764. [Abstract] [Full Text] [PDF]